Omeros Corporation's SEC filings document the regulatory record of a commercial-stage biotechnology company focused on protein and small-molecule therapeutics, including YARTEMLEA, OMS1029 and programs in complement-mediated diseases, cancers, and addictive or compulsive disorders. Form 8-K reports cover operating and financial results, material-event disclosures, clinical and regulatory updates, material agreements, and capital-structure matters.
Proxy materials describe annual shareholder meeting mechanics, director elections, executive-compensation votes, board governance and related shareholder voting matters. The filing record also includes formal disclosure of the FDA approval of YARTEMLEA for TA-TMA and financial-condition information tied to Omeros' commercialization and development-stage pipeline.
Omeros (OMER) has entered into a registered direct offering of 5,365,853 common shares at $4.10, a 14% premium to the 24-Jul-25 close ($3.59). Gross proceeds total $22.0 million; after the 6% placement fee to D. Boral Capital ($1.32 million) and other expenses, net cash is expected at roughly $20.3 million.
The raise increases shares outstanding from 61.8 million to 67.1 million (≈8.7% dilution) and lifts available cash from ≈$26 million (18-Jul-25) to >$45 million, funding general corporate uses, clinical and pre-clinical pipeline work and working capital. Management retains broad spending discretion.
Key pipeline points: FDA’s BLA for lead MASP-2 antibody narsoplimab in TA-TMA now carries a 26-Dec-25 PDUFA date; EMA review is ongoing with an opinion expected mid-2026. The company is also advancing MASP-3 inhibitor zaltenibart (PNH, C3G) and PDE7 program OMS527 (cocaine use disorder). Omeros is negotiating a potential multi-billion-dollar asset deal that could retire its $67.1 million term loan and part of its 2026 notes.
Despite the premium pricing, the offer adds to a $(193 million) adjusted tangible book deficit and follows an auditor going-concern warning. Investors face immediate dilution of $7.15 per share (net tangible book value basis) and future overhang from 19.6 million outstanding options and convertible notes.
Omeros Corporation (OMER) – Form 4 filing dated 07/01/2025
Non-employee director Dr. Peter A. Demopulos was automatically granted a stock option for 15,000 common shares under the company’s director compensation policy following the annual shareholder meeting on 06/27/2025. The option’s key terms are:
- Exercise price: $3.20 per share
- Expiration: 06/27/2035 (10-year tenor)
- Vesting: fully vests the day before the 2026 annual meeting, contingent on continued board service
- Ownership designation: direct (D); post-grant derivative holdings reported at 15,000 options
The filing reflects routine annual equity compensation for board members and does not disclose any open-market purchases or sales of common shares.